Lv5
874 积分 2020-10-22 加入
426P Phase II study of first-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy for extensive-stage small cell lung cancer (ES-SCLC): Updated efficacy and safety results
2个月前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
2个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
9个月前
已关闭
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
10个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
10个月前
已完结
Osimertinib in EGFR-Mutated Lung Cancer
10个月前
已完结
Pathogen Recognition and Innate Immunity
10个月前
已完结
Toll-like receptors and innate immunity
10个月前
已完结
Immunogenic cell stress and death
10个月前
已完结
Vitamin D: immune function, inflammation, infections and auto-immunity
1年前
已完结
皖公网安备34019202002308
